NO961814D0 - Substituted di- and tripetide inhibitors for protein: farnesyl transferase - Google Patents

Substituted di- and tripetide inhibitors for protein: farnesyl transferase

Info

Publication number
NO961814D0
NO961814D0 NO961814A NO961814A NO961814D0 NO 961814 D0 NO961814 D0 NO 961814D0 NO 961814 A NO961814 A NO 961814A NO 961814 A NO961814 A NO 961814A NO 961814 D0 NO961814 D0 NO 961814D0
Authority
NO
Norway
Prior art keywords
tripetide
inhibitors
protein
substituted
farnesyl transferase
Prior art date
Application number
NO961814A
Other languages
Norwegian (no)
Other versions
NO961814L (en
Inventor
Gary Louis Bolton
Mark Wallace Creswell
John Cooke Hodges
Michael William Wilson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO961814D0 publication Critical patent/NO961814D0/en
Publication of NO961814L publication Critical patent/NO961814L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO961814A 1993-11-05 1996-05-03 Substituted di- and tripetide inhibitors for protein: farnesyl transferase NO961814L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14873593A 1993-11-05 1993-11-05
US30330194A 1994-09-13 1994-09-13
PCT/US1994/011553 WO1995012612A1 (en) 1993-11-05 1994-10-12 Substituted di- and tripeptide inhibitors of protein:farnesyl transferase

Publications (2)

Publication Number Publication Date
NO961814D0 true NO961814D0 (en) 1996-05-03
NO961814L NO961814L (en) 1996-05-06

Family

ID=26846110

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961814A NO961814L (en) 1993-11-05 1996-05-03 Substituted di- and tripetide inhibitors for protein: farnesyl transferase

Country Status (10)

Country Link
EP (1) EP0730605A1 (en)
JP (1) JP3597863B2 (en)
KR (1) KR100362338B1 (en)
AU (1) AU681454B2 (en)
CA (1) CA2170766A1 (en)
FI (1) FI961819A (en)
HU (1) HUT75308A (en)
NO (1) NO961814L (en)
NZ (1) NZ275691A (en)
WO (1) WO1995012612A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT72440A (en) * 1994-03-31 1996-04-29 Bristol Myers Squibb Co Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
US5652257A (en) * 1994-09-29 1997-07-29 Merck & Co., Inc. Heterocycle-containing inhibitors of farnesyl-protein transferase
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996010034A2 (en) * 1994-09-29 1996-04-04 Merck & Co., Inc. Thiol-free inhibitors of farnesyl-protein transferase
US5585359A (en) * 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972984A (en) * 1995-06-06 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2736641B1 (en) * 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
GEP20012500B (en) * 1996-05-22 2001-07-25 Warner Lambert Co Inhibitors of Protein Farnesyl Transferase
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
DK0951471T3 (en) 1996-12-17 2004-07-19 Warner Lambert Co Cycloalkyl inhibitors of protein farnesyl transferase
FR2757855B1 (en) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6013662A (en) * 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6124465A (en) * 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6423689B1 (en) 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
KR20010052171A (en) 1998-04-02 2001-06-25 알. 제이. 레이놀즈 터베코 컴퍼니 Pharmaceutical compositions and methods for use
JP2002513031A (en) 1998-04-27 2002-05-08 ワーナー−ランバート・カンパニー Glycinamide derivatives with functionalized alkyl and alkenyl side chains as farnesyltransferase inhibitors
EP1137661A1 (en) * 1998-12-10 2001-10-04 F. Hoffmann-La Roche Ag Procollagen c-proteinase inhibitors
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
FR2796641B1 (en) 1999-07-22 2001-09-21 Aventis Pharma Sa NOVEL PROCESS FOR THE PREPARATION OF BENZOPERHYDROISOINDOLE COMPOUNDS
JPWO2005044780A1 (en) * 2003-11-10 2007-05-17 杏林製薬株式会社 Aminocarboxylic acid derivatives and their addition salts and S1P receptor modulators
ES2382814T3 (en) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EA018917B1 (en) 2006-04-19 2013-11-29 Новартис Аг 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2109608T3 (en) 2007-01-10 2011-08-31 Msd Italia Srl Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
JP5501227B2 (en) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 4-Carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5452237B2 (en) 2008-02-07 2014-03-26 杏林製薬株式会社 Therapeutic or prophylactic agent for inflammatory bowel disease comprising an amino alcohol derivative as an active ingredient
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
AU2011227643A1 (en) 2010-03-16 2012-09-20 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (en) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA)
RU2624045C2 (en) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (en) 2011-04-21 2014-04-16 默沙东公司 Insulin-like growth factor-1 receptor inhibitors
ES2820714T3 (en) 2011-10-26 2021-04-22 Allergan Inc Substituted N-urea amino acid amide derivatives as modulators of formylated peptide receptor 1 (FPRL-1) receptor
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
RU2660349C2 (en) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Compositions and methods for treatment of malignant tumour
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072033A1 (en) * 1991-06-28 1992-12-29 Jackson B. Gibbs Non-substrate inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
KR100362338B1 (en) 2003-04-08
AU7976094A (en) 1995-05-23
EP0730605A1 (en) 1996-09-11
FI961819A0 (en) 1996-04-29
NZ275691A (en) 1998-03-25
HUT75308A (en) 1997-05-28
CA2170766A1 (en) 1995-05-11
AU681454B2 (en) 1997-08-28
WO1995012612A1 (en) 1995-05-11
NO961814L (en) 1996-05-06
FI961819A (en) 1996-04-29
JPH09504547A (en) 1997-05-06
JP3597863B2 (en) 2004-12-08
HU9601193D0 (en) 1996-07-29

Similar Documents

Publication Publication Date Title
NO961814D0 (en) Substituted di- and tripetide inhibitors for protein: farnesyl transferase
NO951647D0 (en) Inhibitors for farnesyl protein transferase
NO974457D0 (en) Inhibitors for farnesyl protein transferase
NO941181D0 (en) Heterocyclic inhibitors of farnesyl protein transferase
NO983892D0 (en) Inhibitors of farnesyl protein transferase
NO996571D0 (en) Inhibitors for farnesyl protein transferase
EE9800408A (en) Protein farnesyl transferase inhibitors
FI951554A (en) Imidazole-containing farnesyl protein transferase inhibitors
EP0664789A4 (en) Inhibitors of farnesyl protein transferase.
EP0535730A3 (en) Inhibitors of farnesyl protein transferase
EP0535731A3 (en) Inhibitors of farnesyl protein transferase
EP0696593A3 (en) Inhibitors of farnesyl protein transferase
EE9800146A (en) Farnesyl protein transferase inhibitors (5-imidazolyl) methyl-2-quinolinone derivatives
NO20024950L (en) 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
EP0547669A3 (en) Inhibitors of farnesyl protein transferase
EP0547670A3 (en) Inhibitors of farnesyl protein transferase
EP0547672A3 (en) Inhibitors of farnesyl protein transferase
EP0547671A3 (en) Inhibitors of farnesyl protein transferase
GB9223246D0 (en) Inhibitors of farnesyl protein transferase
GB9223250D0 (en) Inhibitors of farnesyl protein transferase
DE69711081D1 (en) FARNESYL TRANSFERASE INHIBITORS
ZA941902B (en) Heterocyclic inhibitors of farnesyl protein transferase
ITMI930345A0 (en) N-ACIL-PEPTIDES PROTEIN KINASE INHIBITORS
KR940018806U (en) Amusement fittings for easy removal of shoes
SI0725790T1 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application